170 related articles for article (PubMed ID: 25594896)
1. A validated liquid chromatography tandem mass spectrometry method for quantification of erlotinib, OSI-420 and didesmethyl erlotinib and semi-quantification of erlotinib metabolites in human plasma.
Svedberg A; Gréen H; Vikström A; Lundeberg J; Vikingsson S
J Pharm Biomed Anal; 2015 Mar; 107():186-95. PubMed ID: 25594896
[TBL] [Abstract][Full Text] [Related]
2. The quantification of erlotinib (OSI-774) and OSI-420 in human plasma by liquid chromatography-tandem mass spectrometry.
Masters AR; Sweeney CJ; Jones DR
J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Apr; 848(2):379-83. PubMed ID: 17101305
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous quantification of erlotinib, gefitinib, and imatinib in human plasma by liquid chromatography tandem mass spectrometry.
Chahbouni A; den Burger JC; Vos RM; Sinjewel A; Wilhelm AJ
Ther Drug Monit; 2009 Dec; 31(6):683-7. PubMed ID: 19865001
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous determination of erlotinib and its isomeric major metabolites in human plasma using isocratic liquid chromatography-tandem mass spectrometry and its clinical application.
Ishida T; Naito T; Kawakami J
Biomed Chromatogr; 2015 May; 29(5):643-6. PubMed ID: 25296722
[TBL] [Abstract][Full Text] [Related]
5. Method development and validation for simultaneous determination of six tyrosine kinase inhibitors and two active metabolites in human plasma/serum using UPLC-MS/MS for therapeutic drug monitoring.
Zhang M; Liu X; Chen Z; Jiang S; Wang L; Tao M; Miao L
J Pharm Biomed Anal; 2022 Mar; 211():114562. PubMed ID: 35124453
[TBL] [Abstract][Full Text] [Related]
6. Bioanalysis of erlotinib, its O-demethylated metabolites OSI-413 and OSI-420, and other metabolites by liquid chromatography-tandem mass spectrometry with additional ion mobility identification.
Rood JJM; Toraño JS; Somovilla VJ; Beijnen JH; Sparidans RW
J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Mar; 1166():122554. PubMed ID: 33540147
[TBL] [Abstract][Full Text] [Related]
7. Quantification of tamoxifen and three of its phase-I metabolites in human plasma by liquid chromatography/triple-quadrupole mass spectrometry.
Binkhorst L; Mathijssen RH; Ghobadi Moghaddam-Helmantel IM; de Bruijn P; van Gelder T; Wiemer EA; Loos WJ
J Pharm Biomed Anal; 2011 Dec; 56(5):1016-23. PubMed ID: 21872414
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous and rapid determination of gefitinib, erlotinib and afatinib plasma levels using liquid chromatography/tandem mass spectrometry in patients with non-small-cell lung cancer.
Hayashi H; Kita Y; Iihara H; Yanase K; Ohno Y; Hirose C; Yamada M; Todoroki K; Kitaichi K; Minatoguchi S; Itoh Y; Sugiyama T
Biomed Chromatogr; 2016 Jul; 30(7):1150-1154. PubMed ID: 26525154
[TBL] [Abstract][Full Text] [Related]
9. Development and validation of a sensitive LC-MS/MS assay for the simultaneous quantification of allitinib and its two metabolites in human plasma.
Lin L; Gao Z; Chen X; Zhong D
J Pharm Biomed Anal; 2013 Dec; 86():49-55. PubMed ID: 23973791
[TBL] [Abstract][Full Text] [Related]
10. Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung cancer patients.
Reis R; Labat L; Allard M; Boudou-Rouquette P; Chapron J; Bellesoeur A; Thomas-Schoemann A; Arrondeau J; Giraud F; Alexandre J; Vidal M; Goldwasser F; Blanchet B
J Pharm Biomed Anal; 2018 Sep; 158():174-183. PubMed ID: 29883880
[TBL] [Abstract][Full Text] [Related]
11. A new HILIC-MS/MS method for the simultaneous analysis of carbidopa, levodopa, and its metabolites in human plasma.
Vilhena Rde O; Pontes FL; Marson BM; Ribeiro RP; de Carvalho KA; Cardoso MA; Pontarolo R
J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Sep; 967():41-9. PubMed ID: 25063927
[TBL] [Abstract][Full Text] [Related]
12. Fast quantification of ten psychotropic drugs and metabolites in human plasma by ultra-high performance liquid chromatography tandem mass spectrometry for therapeutic drug monitoring.
Ansermot N; Brawand-Amey M; Kottelat A; Eap CB
J Chromatogr A; 2013 May; 1292():160-72. PubMed ID: 23380367
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.
Haouala A; Zanolari B; Rochat B; Montemurro M; Zaman K; Duchosal MA; Ris HB; Leyvraz S; Widmer N; Decosterd LA
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Jul; 877(22):1982-96. PubMed ID: 19505856
[TBL] [Abstract][Full Text] [Related]
14. Specific method for determination of OSI-774 and its metabolite OSI-420 in human plasma by using liquid chromatography-tandem mass spectrometry.
Zhao M; He P; Rudek MA; Hidalgo M; Baker SD
J Chromatogr B Analyt Technol Biomed Life Sci; 2003 Aug; 793(2):413-20. PubMed ID: 12906916
[TBL] [Abstract][Full Text] [Related]
15. Quantification of etravirine (TMC125) in plasma, dried blood spots and peripheral blood mononuclear cell lysate by liquid chromatography tandem mass spectrometry.
Ter Heine R; Rosing H; van Gorp EC; Mulder JW; Beijnen JH; Huitema AD
J Pharm Biomed Anal; 2009 Feb; 49(2):393-400. PubMed ID: 19059744
[TBL] [Abstract][Full Text] [Related]
16. An LC-MS/MS method for the quantitation of cabozantinib in rat plasma: application to a pharmacokinetic study.
Su Q; Li J; Ji X; Li J; Zhou T; Lu W; Li L
J Chromatogr B Analyt Technol Biomed Life Sci; 2015 Mar; 985():119-23. PubMed ID: 25678398
[TBL] [Abstract][Full Text] [Related]
17. Method development and validation for the quantification of dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, sorafenib and sunitinib in human plasma by liquid chromatography coupled with tandem mass spectrometry.
Lankheet NA; Hillebrand MJ; Rosing H; Schellens JH; Beijnen JH; Huitema AD
Biomed Chromatogr; 2013 Apr; 27(4):466-76. PubMed ID: 22987603
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous determination of gefitinib and its major metabolites in mouse plasma by HPLC-MS/MS and its application to a pharmacokinetics study.
Zheng N; Zhao C; He XR; Jiang ST; Han SY; Xu GB; Li PP
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Feb; 1011():215-22. PubMed ID: 26795401
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous quantification of atorvastatin, erlotinib and OSI-420 in rat serum and liver microsomes using a novel liquid chromatography-mass spectrometry method.
Rysz MA; Kinzi J; Schäfer AM; In-Albon K; Zürcher S; Schmidlin S; Seibert I; Schwardt O; Ricklin D; Meyer Zu Schwabedissen HE
J Pharm Biomed Anal; 2023 Nov; 236():115716. PubMed ID: 37722165
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous quantitative detection of afatinib, erlotinib, gefitinib, icotinib, osimertinib and their metabolites in plasma samples of patients with non-small cell lung cancer using liquid chromatography-tandem mass spectrometry.
Xiong X; Zhang Y; Wang Z; Zhou C; Yang P; Du X; Yang L; Liu W
Clin Chim Acta; 2022 Feb; 527():1-10. PubMed ID: 34999058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
